{
  "story_id": "7e34809efc3612631cdc94f45da2d89b",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-01T20:50:57.000Z",
  "content_hash": "4dfffb1bb24f039a9989524aaf1b95727c99a5b10027a0f0e65c405becc931af",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Rising GLP-1 Use in Dermatology Increases Medicolegal Risks for Physicians",
    "dek": "A medicolegal review warns that expanding off-label GLP-1 use in dermatology increases liability exposure for physicians.",
    "prose": "A review of the LexisNexis legal research database identified 21 medical liability cases involving GLP-1 receptor agonists through February 2026, with only six cases occurring since 2021. [^1]\n\nA press release from Eli Lilly reported that adults with moderate to severe psoriatic disease and overweight or obesity saw sustained or continued improvement in disease activity at 52 weeks with tirzepatide plus ixekizumab versus ixekizumab monotherapy. [^2]\n\nOf the 15 cases before 2021, 10 involved failure-to-warn claims related to pancreatitis and pancreatic cancer, whereas the six newer cases involved allegations of commercial fraud or prescribing-related negligence. [^3]\n\nIn the TOGETHER-PsA trial, 39.2% of the combination group achieved the primary outcome of 50% or greater reduction in psoriatic arthritis disease activity based on American College of Rheumatology 50 plus at least 10% weight loss by week 52, compared to 1.7% in the monotherapy group. [^4]\n\nIn the TOGETHER-PsO trial, more than 40% of participants receiving combination therapy achieved complete skin clearance by week 52 versus 29.1% in the monotherapy group. [^5]",
    "cited": "[{\"statement\":\"A review of the LexisNexis legal research database identified 21 medical liability cases involving GLP-1 receptor agonists through February 2026, with only six cases occurring since 2021.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T20:50:57.000Z\",\"publisher_count\":1,\"sources\":[\"MedpageToday\"]},{\"statement\":\"A press release from Eli Lilly reported that adults with moderate to severe psoriatic disease and overweight or obesity saw sustained or continued improvement in disease activity at 52 weeks with tirzepatide plus ixekizumab versus ixekizumab monotherapy.\",\"source\":\"healio.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T17:31:12.000Z\",\"publisher_count\":1,\"sources\":[\"healio.com\"]},{\"statement\":\"Of the 15 cases before 2021, 10 involved failure-to-warn claims related to pancreatitis and pancreatic cancer, whereas the six newer cases involved allegations of commercial fraud or prescribing-related negligence.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T20:50:57.000Z\",\"publisher_count\":1,\"sources\":[\"MedpageToday\"]},{\"statement\":\"In the TOGETHER-PsA trial, 39.2% of the combination group achieved the primary outcome of 50% or greater reduction in psoriatic arthritis disease activity based on American College of Rheumatology 50 plus at least 10% weight loss by week 52, compared to 1.7% in the monotherapy group.\",\"source\":\"healio.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T17:31:12.000Z\",\"publisher_count\":1,\"sources\":[\"healio.com\"]},{\"statement\":\"In the TOGETHER-PsO trial, more than 40% of participants receiving combination therapy achieved complete skin clearance by week 52 versus 29.1% in the monotherapy group.\",\"source\":\"healio.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T17:31:12.000Z\",\"publisher_count\":1,\"sources\":[\"healio.com\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "8003904d1417d55b858c76a364772f07",
      "thread_id": "79b7b2cc7ab0ac3cba9d4fe88c77f455",
      "thread_label": "ixekizumab",
      "novelty": "UPDATE",
      "content_hash": "6dd470af0152b5cb734e60f4b2c04468bb64999bc6c11da08148f0c6da0d4809",
      "last_published_at": "2026-09-01T20:50:57.000Z",
      "read_receipt": {
        "slice_hash": "c586ff339b40999b8ce111cdfca5bbf52c09e667949dbbd7bfae80ceba9a8dec",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDFUMjA6NDA6MDAuMDAwMDAwWiIsImlkIjoiNWU3YmZmMzFiNmRmMjQyMDRjNjBmZDViYTU3OWZlZjAiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDFUMjE6MDg6MTIuMDAwMDAwWiIsImlkIjoiMDZhY2FlZmQxZDE2ZTE3MzJhY2JiOWMxMzhmNmU0MTciLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12017721,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "L9f6uqFsvNZ-nrZ0c09BUWR_h1TqK8D46S-msn1pgmeX59tYcgHMPjGMTehvwf0OVyfQjpaWDJ6DapPCBe28AQ",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-02T22:16:28.393Z"
  },
  "cited_facts": [
    {
      "statement": "A review of the LexisNexis legal research database identified 21 medical liability cases involving GLP-1 receptor agonists through February 2026, with only six cases occurring since 2021.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T20:50:57.000Z",
      "publisher_count": 1,
      "sources": [
        "MedpageToday"
      ]
    },
    {
      "statement": "A press release from Eli Lilly reported that adults with moderate to severe psoriatic disease and overweight or obesity saw sustained or continued improvement in disease activity at 52 weeks with tirzepatide plus ixekizumab versus ixekizumab monotherapy.",
      "source": "healio.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T17:31:12.000Z",
      "publisher_count": 1,
      "sources": [
        "healio.com"
      ]
    },
    {
      "statement": "Of the 15 cases before 2021, 10 involved failure-to-warn claims related to pancreatitis and pancreatic cancer, whereas the six newer cases involved allegations of commercial fraud or prescribing-related negligence.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T20:50:57.000Z",
      "publisher_count": 1,
      "sources": [
        "MedpageToday"
      ]
    },
    {
      "statement": "In the TOGETHER-PsA trial, 39.2% of the combination group achieved the primary outcome of 50% or greater reduction in psoriatic arthritis disease activity based on American College of Rheumatology 50 plus at least 10% weight loss by week 52, compared to 1.7% in the monotherapy group.",
      "source": "healio.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T17:31:12.000Z",
      "publisher_count": 1,
      "sources": [
        "healio.com"
      ]
    },
    {
      "statement": "In the TOGETHER-PsO trial, more than 40% of participants receiving combination therapy achieved complete skin clearance by week 52 versus 29.1% in the monotherapy group.",
      "source": "healio.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T17:31:12.000Z",
      "publisher_count": 1,
      "sources": [
        "healio.com"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}